-
Mashup Score: 18Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma - 9 hour(s) ago
This cohort study assesses treatment patterns and attrition rates in patients with advanced urothelial carcinoma in US oncology clinics.
Source: jamanetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 18Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma - 19 hour(s) ago
This cohort study assesses treatment patterns and attrition rates in patients with advanced urothelial carcinoma in US oncology clinics.
Source: jamanetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 9
APCCC 2024, Brazilian Unified Healthcare System, cancer epidemiology in Latin America, LACOG 0218 HERCULES trial, REDEMPTED trial.
Source: www.urotoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
La acreditación premia la excelencia en la prestación del servicio de información a pacientes que sufren estas patologías.
Source: gacetamedica.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35Location, location, location: Protein kinase nanoclustering for optimised signalling output - 12 day(s) ago
This article reviews the latest studies that have used super-resolution microscopy and cluster analysis methodologies to study the mechanism of protein kinase signalling hubs and their organisation at nanoscale.
Source: elifesciences.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Frontiers | A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma - 21 day(s) ago
In the advanced renal cell carcinoma (RCC) scenario, there are no consistent biomarkers to predict the clinical benefit patients derived from immune checkpoi…
Source: www.frontiersin.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 6
Prostate Cancer and Prostatic Diseases – Application of next-generation imaging in biochemically recurrent prostate cancer
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35Location, location, location: Protein kinase nanoclustering for optimised signalling output - 25 day(s) ago
This article reviews the latest studies that have used super-resolution microscopy and cluster analysis methodologies to study the mechanism of protein kinase signalling hubs and their organisation at nanoscale.
Source: elifesciences.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Ken Herrmann on LinkedIn: Novartis confirms plans to file for Pluvicto® pre-taxane label expansion… - 27 day(s) ago
PSMAFORE UPDATE: OS hazard ratio less than 1.0 (HR<1.0) in the intent-to-treat (ITT) population unadjusted for cross-over. This is excellent for patients and…
Source: www.linkedin.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22
PURPOSE Patients with no evidence of disease (NED) after metastasectomy for renal cell carcinoma are at high risk of recurrence. Pazopanib is an inhibitor of vascular endothelial growth factor receptor and other kinases that improves progression-free survival in patients with metastatic RCC (mRCC). We conducted a randomized, double-blind, placebo-controlled multicenter study to test whether pazopanib would improve disease-free survival (DFS) in patients with mRCC rendered NED after metastasectomy. PATIENTS AND METHODS Patients with NED after metastasectomy were randomly assigned 1:1 to receive pazopanib 800 mg once daily versus placebo for 52 weeks. The study was designed to observe an improvement in DFS from 25% to 45% with pazopanib at 3 years, corresponding to 42% reduction in the DFS event rate. RESULTS From August 2012 to July 2017, 129 patients were enrolled. The study was unblinded after 83 DFS events (92% information). The study did not meet its primary end point. An updated an
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US | Oncology | JAMA Network Open | JAMA Network https://t.co/0tW8pJDfHj